Efficacy of percutaneous closure of patent foramen ovale in preventing recurrent events, compared with standard medical therapy in patients with cryptogenic ischemic stroke: Systematic review and meta-analysis;Eficacia del cierre percutáneo del foramen oval permeable en la prevención de eventos recurrentes comparado con el tratamiento médico estándar en pacientes con EVC isquémica criptogénica: Revisión sistemática y meta-análisis

Revista Mexicana de Neurociencia

Volumn 14, Issue 6, 2013, Pages 299-305

  Salas Gutiérrez, Irving ^a   Reyes Melo, Isael ^a   Chiquete, Erwin ^a   Ruiz Flores, Manuel Leonardo ^b   Cantú Brito, Carlos ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Medical treatment; Patent foramen ovale; Percutaneous closure; Stroke; Transient ischemic attack

Indexed keywords

CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; HEART SURGERY; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MORTALITY; PATENT FORAMEN OVALE; PERCUTANEOUS CLOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

EID: 84891908981     PISSN: 16655044     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009; 40: 1195-203.
2. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O'Fallon WM, Pascoe RD, et al. Prevalence ofpotential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc 1999; 74: 862-9.
3. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 1172-9.
4. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009; 40: 2349-55.
5. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent orguilty? Evidence from a prospective population-based study. J Am CollCardiol 2006; 47: 440-5.
6. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patentforamen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transientischemic attack. Am Heart J 1995; 130: 1083-8.
7. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associatedwith patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740-6.
8. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyondequipoise. JAMA 2005; 294: 366-9.
9. Dalen JE. Are patients with a patent foramen ovale at increased risk of stroke?A billion dollar question. Am J Med 2007; 120: 472-4.
10. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenicstroke with patent foramen ovale. N Engl J Med 2012; 366: 991-9.
11. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083-91.
12. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092-100.
13. Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, Dinicolantonio JJ, Lansky AJ, et al. Stroke prevention by percutaneous closure of patent foramen ovale: asystematic review and meta-analysis. Heart 2013; 21. [Epub ahead of print].